According to Tibet Pharmaceutical's announcement, the company plans to implement differentiated dividends for the first half year of 2026, with a cash dividend of 1.146 yuan per share, based on a total share capital of 322 million shares after deducting 4.01 million shares in the special repurchase account. In total, it plans to distribute a cash dividend of 365 million yuan, accounting for 60.00% of net profit due to mother for the half year. The repurchase of shares in the special account did not participate in this profit distribution. This differentiated equity distribution had an impact of about 0.05% on the exclusion ex-interest reference price, with little impact. Taihetai Law Firm believes that this differentiated dividend complies with relevant regulations and does not harm the interests of the company or shareholders.

According to Tibet Pharmaceutical's announcement, the company plans to implement differentiated dividends for the first half year of 2026, with a cash dividend of 1.146 yuan per share, based on a total share capital of 322 million shares after deducting 4.01 million shares in the special repurchase account. In total, it plans to distribute a cash dividend of 365 million yuan, accounting for 60.00% of net profit due to mother for the half year. The repurchase of shares in the special account did not participate in this profit distribution. This differentiated equity distribution had an impact of about 0.05% on the exclusion ex-interest reference price, with little impact. Taihetai Law Firm believes that this differentiated dividend complies with relevant regulations and does not harm the interests of the company or shareholders.